Gross profit margin of selected biotech and drugs companies as of Q3 2014
Find more statistics at Statista
Celgene Corporation is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Alexion Pharmaceuticals' first commercial product is Soliris® (eculizumab), the world's first and only approved terminal complement inhibitor. Other highly innovative therapeutic candidates include asfotase alfa for patients with hypophosphatasia; ALXN1101, a cPMP replacement therapy for patients with molybdenum cofactor deficiency Type A; and ALXN1007, a novel anti-inflammatory antibody.
Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products. Their leading products include BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, BOTOX® Cosmetic (onabotulinumtoxinA), and the JUVÉDERM® family of dermal fillers.
Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products address diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, Crohn’s disease, and psoriasis.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics for HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie's core areas of focus include immunology, kidney disease, liver disease, neuroscience, oncology and women’s health.
Actavis is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis has acquired Forest Laboratories in July 2014 and Allergan in November 2014, making it the fastest growing, most dynamic pharmaceutical company in global healthcare.
Mylan Laboratories is one of the largest generics and specialty pharmaceutical companies in the world. It is also one of the world’s largest producers of API for generic antiretrovirals (ARVs) for the treatment of HIV/AIDS, as well as antibacterials, central nervous system agents, antihistamines/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management medicines.
Hospira is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. It is the only North American company to offer biosimilars on market in Europe and Australia.